Tagged with S

Turkey Kazim Dinç, chairman of the board of SURDER and former Minister of Health of Turkey, offers his insights into the Turkish OTC and health products market, highlighting the challenges facing the industry and SURDER’s role in bringing about constructive reforms.   Before SURDER was established, there was a sizeable gap…

Korea In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of the leading Contract Development Manufacturing Organisations (CDMO) in the market in only seven years. Dr Kim also provides his assessment…

Malaysia Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to healthcare professionals and patients in the country. He also highlights his future plans for the affiliate to bring more innovative…

Turkey Despite the sharp decline in the Turkish lira’s value, the general mood among pharmaceutical executives in Turkey is positive. Rather than being discouraged, they are calling upon their resiliency and experience from former periods of economic fluctuation to push the Turkish healthcare and life sciences sector forward.   Turkey made…

Korea Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the potential implications for the US-Korea FTA renegotiations.   The rate [of ageing] in Korea is actually even more serious than…

Malaysia Dr Hyzan Mohd Yusof, CEO at OSA Technology, tells the story of how he founded the company to address Malaysia’s unmet needs in medical devices as well as his vision on the next steps the government should take to boost the sector.   Having our own manufacturing plant is a…

Spain Fernando Álvarez, director general of Allergan Iberia, highlights the market’s shift towards more holistic innovation and the company’s main growth drivers, especially in the field of aesthetics. Furthermore, he touches on the importance of the market access team in the fragmented Spanish healthcare ecosystem and his ambitions for Allergan throughout…

Malaysia How Malaysia is setting itself up to provide biosimilars across the Islamic world as well as Asia.   Inno Bio Ventures, a Malaysian state-owned company originally set up to create drug security by ensuring that the country was self-sufficient in terms of medicine supply, has been making its first moves…

Spain Although death rates due to cardiovascular diseases in Spain are among the lowest in the EU, they represent the main cause of death in Spain, accounting for 30% of all deaths in 2014 (33% of deaths among women and 27% among men). Cancer is the second most important cause of…

Patients There are around 2 billion people in the world that do not have access to the medicines they need. This week the 2018 Access to Medicine Index was published revealing that there is a handful of pharmaceutical companies developing the bulk of urgently needed new medicines for the poor. The…

Malaysia Dr Ramli Zainal, the director at National Pharmaceutical Regulatory Agency (NPRA), expresses the continuous work of NPRA to build a strong regulatory ecosystem in Malaysia and the important role that the Malaysian regulator has in the ASEAN region. He also takes time to explain the upcoming priorities to further establish…

France Thomas Courbe, general director of the DGE (Direction Générale des Entreprises – General Directorate for Enterprises), speaks about the role of the DGE and the implementation of new policies oriented towards France’s new pro-business direction, specifically in the life sciences industry.   France is becoming the pro-business model in Europe.…